http://www.bccancer.bc.ca/drug-database-site/drug%20index/cyclophosphamide_monograph_1june2013_formatted.pdf WebChanges in chemotherapy protocols have influenced the risk and rate of secondary malignancies in high-risk populations. The alkylating agents, topoisomerase inhibitors, and anthracycline agents pose the highest risk of initiating carcinogenesis.
Cyclophosphamide - an overview ScienceDirect Topics
WebAug 19, 2024 · Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Minimal Change Nephrotic Syndrome In Pediatric Patients Web5.5 Secondary Malignancies . 5.6 Veno-occlusive Liver Disease 5.7 Alcohol Content . 5.8 Embryo-Fetal Toxicity 5.9 Infertility . ... be administered to reduce the risks of neutropenia complications associated with cyclophosphamide use. Primary and secondary prophylaxis with G -CSF should be considered in all patients considered to be at dutch master palmer
Cyclophosphamide Monograph for Professionals - Drugs.com
WebApr 12, 2024 · Most of those pediatric malignancies (5 of 8) occurred after myeloablative busulfan/cyclophosphamide conditioning with a short latency of ≤5 years while secondary hematologic malignancies were mainly confined to the adult age group. ... The minimization of secondary malignancy risk is of particular importance, ... WebJan 6, 2024 · It’s more common with some medications, though, such as etoposide, which is used to treat testicular cancer and lung cancer, and cyclophosphamide, which is used to treat breast cancer and ovarian cancer. What kind of follow-up care is needed to monitor patients for secondary cancers? WebWhat is cyclophosphamide? Cyclophosphamide is used to treat breast cancer, lung cancer, leukaemia, lymphoma and myeloma. It may sometimes be used to treat other … imyfone d-back hard drive recovery